Selvavinayagam Sivaprakasam T, Sankar Sathish, Yong Yean K, Murugesan Amudhan, Suvaithenamudhan Suvaiyarasan, Hemashree Kannan, Rajeshkumar Manivannan, Kumaresan Anandhazhvar, Pandey Ramendra P, Shanmugam Saravanan, Arthydevi Parthiban, Kumar Masilamani S, Gopalan Natarajan, Kannan Meganathan, Cheedarla Narayanaiah, Tan Hong Y, Zhang Ying, Larsson Marie, Balakrishnan Pachamuthu, Velu Vijayakumar, Byrareddy Siddappa N, Shankar Esaki M, Raju Sivadoss
State Public Health Laboratory, Directorate of Public Health and Preventive Medicine, DMS Campus, Teynampet, Chennai 600 006, Tamil Nadu, India.
Department of Microbiology, Centre for Infectious Diseases, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai 600 077, Tamil Nadu, India.
medRxiv. 2024 Apr 19:2024.04.16.24305882. doi: 10.1101/2024.04.16.24305882.
In December 2023, we observed a notable shift in the COVID-19 landscape, when the JN.1 emerged as a predominant SARS-CoV-2 variant with a 95% incidence. We characterized the clinical profile, and genetic changes in JN.1, an emerging SARS-CoV-2 variant of interest. Whole genome sequencing was performed on SARS-CoV-2 positive samples, followed by sequence analysis. Mutations within the spike protein sequences were analyzed and compared with the previous lineages and sublineages of SARS-CoV-2, to identify the potential impact of these unique mutations on protein structure and possible functionality. Several unique and dynamic mutations were identified herein. Our data provides key insights into the emergence of newer variants of SARS-CoV-2 in our region and highlights the need for robust and sustained genomic surveillance of SARS-CoV-2.
2023年12月,我们观察到新冠疫情形势出现显著变化,当时JN.1成为主要的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体,发病率达95%。我们对JN.1这一新兴的值得关注的SARS-CoV-2变体的临床特征和基因变化进行了描述。对SARS-CoV-2阳性样本进行全基因组测序,随后进行序列分析。分析刺突蛋白序列中的突变,并与SARS-CoV-2以前的谱系和亚谱系进行比较,以确定这些独特突变对蛋白质结构和可能功能的潜在影响。本文鉴定出了几个独特且动态的突变。我们的数据为我们所在地区SARS-CoV-2新变体的出现提供了关键见解,并突出了对SARS-CoV-2进行强有力且持续的基因组监测的必要性。